These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Hematologic tumors]. Ogawa M Gan To Kagaku Ryoho; 2003 Oct; 30(10):1416-21. PubMed ID: 14584273 [TBL] [Abstract][Full Text] [Related]
10. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma]. Kamieńska E Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116 [TBL] [Abstract][Full Text] [Related]
11. Sequential administration of two oncostatic drugs: study of modalities for pharmacodynamic potentiation. Pouillart R; Huong TH; Brugerie E; Lheritier J Biomedicine; 1974 Dec; 21(12):471-9. PubMed ID: 4462870 [No Abstract] [Full Text] [Related]
12. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751 [TBL] [Abstract][Full Text] [Related]
13. [Acute non-lymphatic leukemia after treatment of Hodgkin's lymphoma with chemotherapy and radiotherapy]. Lira P; Grebe G Rev Med Chil; 1984 Oct; 112(10):1021-5. PubMed ID: 6085597 [No Abstract] [Full Text] [Related]
14. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
15. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Canellos GP Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509 [TBL] [Abstract][Full Text] [Related]
16. [Non-Hodgkin's lymphomas: recent achievements and therapeutic perspectives]. Bron D; Vandenheule B; Stryckmans P Rev Med Brux; 1985 Sep; 6(7):491-5. PubMed ID: 2417298 [No Abstract] [Full Text] [Related]
17. MOPP, ABVD, or both to treat Hodgkin's disease. Martino R; Nomdedeu J; Brunet S N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766 [No Abstract] [Full Text] [Related]
18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
19. [Efficacy of lomustine, teniposide, doxorubicin, bleomycin and prednisone (LTABP) or adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) in the treatment of malignant lymphogranulomatosis resistant to MOPP]. Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Kowalczyński M; Urbańska-Ryś H Pol Tyg Lek; 1990 May 21-28; 45(21-22):426-9. PubMed ID: 1702536 [TBL] [Abstract][Full Text] [Related]
20. [Results of treating lymphomas with high degree of malignancy using COPP, CHOP-Bleo and MEV protocols]. Płuzańska A; Krykowski E; Robak T; Oliskiewicz W; Polkowska E; Dowgier I; Hyjek E Pol Tyg Lek; 1982 Sep; 37(36):1049-53. PubMed ID: 6189105 [No Abstract] [Full Text] [Related] [Next] [New Search]